Bruker Corp. (Nasdaq: BRKR), a $2.1b manufacturer of analytical and diagnostic platforms and instruments is acquiring Canopy Biosciences, a developer of multiplex biomarker imaging technologies for immunology, immuno-oncology and cell therapy to boost Bruker’s CRISPR (clustered regularly interspaced short palindromic repeats) gene editing research capabilities and biopharma drug development business. Canopy Biosciences’ multi-omic (biological analysis) capabilities for immune profiling include ultrasensitive DNA sequencing, gene expression analysis, and multiplexed protein detection in cells and tissue samples. Canopy Biosciences was backed by private equity firm Ampersand Capital. Terms not announced.
Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare Mergers, Biopharmaceuticals, Immunology